SCHEMBL2069262

SCHEMBL2069262

Cc1nc(-c2ccc(Cl)cc2)sc1C(=O)NCC1CCNC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
PPARA Q07869 6/20 0.56
CHRM4 P08173 2/20 0.55
RAB9A P51151 3/20 0.51
NPC1 O15118 3/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
PPARD Q03181 1/20 0.49
HPGD P15428 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
XDH P47989 1/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2071887 0.94 PPARA (0.57) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2069694 0.93 PPARA (0.58) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2068822 0.83 PPARA (0.58) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2069804 0.78 PPARA (0.59) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2068820 0.78 PPARA (0.59) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2069652 0.78 MAPT (0.57) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2068818 0.78 PPARA (0.59) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL2069312 0.75 PPARA (0.60) GAASMN1; SMN2PPARACHRM4RAB9A
SCHEMBL8255991 0.75 SMYD3 (0.58)
SCHEMBL14800165 0.75 GAA (1.00) GAASMN1; SMN2PPARARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-7902367-B2 Cyclic amino benzoic acid derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 US disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed
EP-1780210-A1 NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249580-A1 Novel Cyclic Amino Benzoic Acid Derivative PPARA, PPARG, PPARD GAA 3876/4885SMN1; SMN2 4185/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.